BioConnection proudly announced that it has won the FD Gazellen status. This prestigious award is given by the Financieele Dagblad to financially healthy companies that have reached a yearly revenue growth of more than 20% in the last three years. BioConnection is a Contract Development and Manufacturing Organization for the development and production of injectable (bio)pharmaceutical products and is based at Pivot Park.
“We’re very excited to win one of the Gazellen Awards. We have grown fast and steady in recent years. The highlight came earlier this year when we acquired the Aletta Jacobs building from MSD enabling us to have our own manufacturing facility and expand our capabilities and capacity, tells Alexander Willemse, CEO of BioConnection. “It is also a reward for all the employees of BioConnection and their dedicated work and to our customers for their trust in us. We definitely look with confidence to the future.”
BioConnection is a Contract Development and Manufacturing Organization for the development and production of injectable (bio)pharmaceutical products. BioConnection specializes in: Drug Product development (formulation, analytics, lyophilisation), fill & finish and lyophilisation at clinical and commercial scale. BioConnection offers services based on tailor made solutions and customer-focused flexibility from its own pilot plant and through trusted partners.
About the Gazellen Award
To qualify for an FD Gazellen Award a company must have achieved net sales growth of at least 20 percent per year over the last three years. It is also important that the organization has a stable and healthy financial position. The most recent financial year should be concluded with a positive result and there may only be one year of financial loss in the previous period. On November 24th the official awards ceremony will be held in Eindhoven.